The Journal of Translational Autoimmunity, published by ELSEVIER, stands at the forefront of research in the ever-evolving fields of autoimmunity and immunology. With an ISSN of 2589-9090, this Open Access journal has been committed to facilitating the dissemination of high-quality research since its inception in 2019. Nestled in the Netherlands, it serves as a vital platform for researchers and professionals focused on translating innovative findings into practical applications for autoimmune disorders. The journal has achieved notable recognition, securing a Q2 quartile ranking in both the Immunology and Immunology and Allergy categories, showcasing its influence within the academic community, currently ranking 70th out of 233 in Medicine: Immunology and Allergy and 83rd out of 236 in Immunology and Microbiology: Immunology. By engaging with cutting-edge studies and fostering collaborative research, the Journal of Translational Autoimmunity is not only a cornerstone of academic inquiry but also a beacon of hope for clinical advancements in the management of autoimmune conditions. Researchers, professionals, and students alike are encouraged to contribute and stay abreast of the latest discoveries that hold the potential to transform patient care.

Central European Journal of Immunology is a premier publication dedicated to advancing the field of immunology and allergy research. Established in 1996 and published by TERMEDIA PUBLISHING HOUSE LTD, this open access journal has consistently provided a platform for innovative research and comprehensive reviews since its transition to open access in 2002. With an ISSN of 1426-3912 and E-ISSN of 1644-4124, it embraces a global readership while being rooted in Poland. The journal, with a notable Q3 ranking in both the categories of immunology and allergy in 2023, positions itself within the competitive landscape of scientific discourse, as reflected in its Scopus rankings. Designed for researchers, professionals, and students, the Central European Journal of Immunology not only disseminates significant findings but also fosters collaboration and innovation in the immunological sciences, making it a vital resource for those seeking to stay current in this rapidly evolving field.

Welcome to the American Journal of Clinical and Experimental Immunology, a premier publication dedicated to advancing the fields of clinical and experimental immunology. Published by E-CENTURY PUBLISHING CORP, this journal provides a platform for groundbreaking research, case studies, and comprehensive reviews that contribute to our understanding of the immune system and its implications for health and disease. With a focus on disseminating innovative findings and enhancing the dialogue among researchers, practitioners, and students, the journal aims to bridge the gap between laboratory discoveries and clinical applications. Although specific metrics such as the impact factor and Scopus ranks are currently not provided, the journal is committed to maintaining high standards of scholarly publishing and fostering open access to vital research. Located in Madison, WI, and available online via its E-ISSN 2164-7712, this journal is a valuable resource for those wishing to explore the intricacies of immunological research and its applications in clinical practice.

Acta Dermatovenerologica Alpina Pannonica et Adriatica, published by the Dermatovenereological Society of Slovenia, stands as an important peer-reviewed journal in the fields of dermatology, infectious diseases, and general medicine. Established in 1994, this journal has built a solid reputation over the years, achieving a Q3 ranking in 2023 within its respective categories, which highlights its contribution and relevance in the academic community. With an ISSN of 1318-4458 and E-ISSN of 1581-2979, it aims to disseminate new research findings, review articles, and case reports that impact clinical practice and promote knowledge in dermatovenereology throughout the Alpine and Adriatic regions. Located in Ljubljana, Slovenia, the journal actively supports open access to its publications, ensuring that valuable insights are available to a global audience, which is crucial for advancing medical research and practice. The dedication to quality and scientific rigor makes Acta Dermatovenerologica Alpina Pannonica et Adriatica a must-read for researchers, practitioners, and students aiming to stay informed on the latest advancements in dermatology and related disciplines.

Modern Rheumatology is a premier journal dedicated to advancing the field of rheumatology through high-quality peer-reviewed research. Published by Oxford University Press, this journal reflects the latest developments in rheumatologic medicine, catering to researchers, clinicians, and students alike. With an H-Index highlighting its scholarly impact, Modern Rheumatology occupies a notable position, ranking Q2 in both the fields of Medicine and Rheumatology in 2023, and is listed among the top 25 journals in its category by Scopus. Spanning from the year 2000 to 2024, the journal features a diverse array of topics aimed at addressing current challenges and innovations in the field. Although it does not offer Open Access, it provides essential insights for professionals seeking to stay abreast of evolving treatment modalities and research breakthroughs. Located in the heart of the United Kingdom, Modern Rheumatology is a vital resource for anyone committed to enhancing the understanding and treatment of rheumatic diseases.

Rheumatology & Autoimmunity, published by WILEY, is an emerging academic journal that delves into the intricacies of rheumatological diseases and autoimmune disorders, providing a critical platform for researchers and practitioners within the field. With an ISSN of 2767-1410 and E-ISSN 2767-1429, the journal aims to disseminate cutting-edge research in both clinical and laboratory settings, enhancing knowledge and understanding among professionals and scholars. Although currently classified in Q4 for Immunology and Allergy, and Q3 for Internal Medicine and Rheumatology as of 2023, the journal is positioned for growth and greater visibility in the scientific community. The three-year publishing span from 2021 to 2024 signifies a commitment to addressing contemporary issues and fostering collaboration among various disciplines related to immunology. As an open access journal, it provides wide accessibility, ensuring that groundbreaking research is available to a broad audience. This journal is poised to become a vital resource for those dedicated to advancing the understanding and treatment of autoimmune conditions.

International Immunopharmacology, published by Elsevier, stands as a prominent journal within the disciplines of immunology and pharmacology. With an ISSN of 1567-5769 and an E-ISSN of 1878-1705, this esteemed journal is based in the Netherlands and features a robust commitment to disseminating high-quality research from its inception in 2001 through 2024. The journal has achieved impressive rankings, securing a Q1 category in Pharmacology and Q2 in both Immunology and Immunology and Allergy as of 2023. With its strategic focus on bridging the gap between immunology and pharmacological applications, International Immunopharmacology attracts a diverse readership, including researchers, healthcare professionals, and students interested in the latest advancements in therapeutic agents and immune system modulation. Furthermore, it offers an open access option, enhancing the accessibility and reach of its invaluable content. As a pivotal resource in the field, this journal not only facilitates the exchange of innovative ideas but also fosters a deeper understanding of the complexities of immunopharmacology in today’s research landscape.

AUTOIMMUNITY, published by Taylor & Francis Ltd, is an influential journal dedicated to advancing the understanding of autoimmune diseases through rigorous research and scholarly discourse. With an ISSN of 0891-6934 and an E-ISSN of 1607-842X, this journal serves as a key resource for immunologists, medical professionals, and students engaged in investigating the complex mechanisms underpinning autoimmunity. Operating from the United Kingdom, it offers valuable insights into immunological and allergic phenomena, achieving respectable Scopus rankings in both Immunology and Allergy (106/233, Q3) and Immunology and Microbiology (125/236, Q2). Covering a broad spectrum of topics since its inception in 1988, AUTOIMMUNITY encourages the dissemination of innovative research findings and aims to enhance collaborative efforts within the field. While it currently adopts a conventional access model, the journal's commitment to quality and excellence positions it as a vital platform for those looking to engage with cutting-edge research in immunology.

Welcome to the International Journal of Immunopathology and Pharmacology, a premier publication dedicated to advancing the fields of immunology and pharmacology. Published by SAGE Publications Inc., this Open Access journal has been a vital resource since its inception in 1989, providing an expansive platform for innovative research and comprehensive reviews until 2024. With a strong focus on the mechanisms of immune responses and therapeutic developments, our journal stands out with a 2023 impact factor reflected in its Q3 ranking in Immunology and Allergy, and a Q2 ranking in Pharmacology. The journal's Scopus rankings highlight its significance, ranking #174 in Pharmacology, #141 in Medicine, and #156 in Immunology, all affirming its role in contributing to the broader scientific community. Through rigorous peer review and a commitment to high-quality research, the International Journal of Immunopathology and Pharmacology continues to be an essential resource for scientists, healthcare professionals, and students striving to enhance their knowledge and understanding in these critical fields.

Journal of Translational Medicine, published by BMC in the United Kingdom, stands at the forefront of biomedical research, bridging the gap between laboratory discoveries and clinical applications. Established in 2003 as an Open Access journal, it has garnered significant recognition, achieving a Q1 quartile ranking in both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023. With an impressive Scopus rank of 38 out of 636 in General Medicine and 33 out of 221 in General Biochemistry, Genetics and Molecular Biology, the journal is committed to disseminating high-quality, peer-reviewed research that impacts healthcare and informs clinical practices. By facilitating free access to groundbreaking studies, the Journal of Translational Medicine aims to enhance collaboration among researchers, professionals, and students in the scientific community, fostering advancements in translational research well into the future.